SCHEMBL2278702

SCHEMBL2278702

c1ccc(CNc2c[nH]c3ccccc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.52
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
GABRP O00591 1/20 0.51
GABRD O14764 1/20 0.51
GABRA1 P14867 1/20 0.51
GABRB1 P18505 1/20 0.51
GABRG2 P18507 1/20 0.51
GABRB3 P28472 1/20 0.51
GABRA5 P31644 1/20 0.51
GABRA3 P34903 1/20 0.51
GABRA2 P47869 1/20 0.51
GABRB2 P47870 1/20 0.51
GABRA4 P48169 1/20 0.51
GABRE P78334 1/20 0.51
GABRA6 Q16445 1/20 0.51
GABRG1 Q8N1C3 1/20 0.51
GABRG3 Q99928 1/20 0.51
GABRQ Q9UN88 1/20 0.51
IDO1 P14902 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31744669 0.87 STING1 (0.52) KDRKMT2AMEN1GABRPGABRD
SCHEMBL31744872 0.81 LMNA (0.48) KDRKMT2AMEN1IDO1LMNA
SCHEMBL31744619 0.81 PTPRF (0.55) KDRKMT2AMEN1GABRPGABRD
SCHEMBL701071 0.78 GPR84 (0.47) KMT2AMEN1HSD17B10CYP3A4MAPT
SCHEMBL30753171 0.78 HTR2A (0.51) KMT2AMEN1IDO1HSD17B10CYP3A4
SCHEMBL1260955 0.78 HTR2A (0.51) KMT2AMEN1IDO1HSD17B10CYP3A4
SCHEMBL29577526 0.76 GPR84 (0.51) KMT2AMEN1GABRPGABRDGABRA1
SCHEMBL7311206 0.76 GPR84 (0.51) KMT2AMEN1GABRPGABRDGABRA1
SCHEMBL7507194 0.75 HTR2A (0.49) KMT2AMEN1IDO1HSD17B10CYP3A4
SCHEMBL29611671 0.75 HTR2A (0.49) KMT2AMEN1IDO1HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US claimed
CN-114920775-B Axial chiral bisindole catalyst and synthetic method and application thereof 江苏师范大学 2023-08-04 CN claimed
CN-114920775-A Axial chiral bisindole catalyst and synthesis method and application thereof 江苏师范大学 2022-08-19 CN claimed
CN-101747321-B Indole-3-benzylamine derivative, preparation method and application UNIV ZHEJIANG 2013-01-02 CN claimed
CN-101747321-A Indole-3-benzylamine derivative, preparation method and application UNIV ZHEJIANG 2010-06-23 CN claimed
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
CN-114920775-B Axial chiral bisindole catalyst and synthetic method and application thereof 江苏师范大学 2023-08-04 CN disclosed
CN-114920775-B Axial chiral bisindole catalyst and synthetic method and application thereof 江苏师范大学 2023-08-04 CN disclosed
CN-114920775-A Axial chiral bisindole catalyst and synthesis method and application thereof 江苏师范大学 2022-08-19 CN disclosed
CN-114920775-A Axial chiral bisindole catalyst and synthesis method and application thereof 江苏师范大学 2022-08-19 CN disclosed
EP-2367812-B1 [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4TRIFLUOROMETHOXY-1H-INDOL-3-YL]METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE SANOFI SA (FR) 2015-09-16 EP disclosed
US-20110201647-A1 [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE SANOFI-AVENTIS (FR) 2011-08-18 US disclosed
CN-102149705-A [4- (5-aminomethyl-2-fluorophenyl) -piperidin-1-yl ] - [ 7-fluoro-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl ] -methanone as mast cell tryptase inhibitor SANOFI AVENTIS 2011-08-10 CN disclosed
WO-2010022196-A3 [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE SANOFI-AVENTIS (FR) 2010-07-22 WO disclosed
CN-101747321-A Indole-3-benzylamine derivative, preparation method and application UNIV ZHEJIANG 2010-06-23 CN disclosed
CN-101747321-A Indole-3-benzylamine derivative, preparation method and application UNIV ZHEJIANG 2010-06-23 CN disclosed
CN-101747321-A Indole-3-benzylamine derivative, preparation method and application UNIV ZHEJIANG 2010-06-23 CN disclosed
WO-2010022196-A2 [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE SANOFI-AVENTIS (FR) 2010-02-25 WO disclosed
WO-2010022196-A2 [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE SANOFI-AVENTIS (FR) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201647-A1 [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE CMA1, TPSAB1, TPSB2 KDR 3726/4885KMT2A 1161/4885MEN1 2128/4885
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 KDR 4699/4885KMT2A 4633/4885MEN1 2402/4885
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 KDR 4699/4885KMT2A 4633/4885MEN1 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.